Ying-Chin L, Shou-Chu C, Pai-Tsang H, Hung-Yi C

Language: English
References: 21
Page: 125-132
PDF size: 82.01 Kb.

ABSTRACT

Background and rationale for the study. Ultrasound assessment of the severity of non-alcoholic fatty liver disease (NAFLD) shows substantial observer variability. The purpose of this retrospective study is to develop a more objective, quantitative, and applicable assessment method for all physicians. Main Results. Male gender, and increases in age, body mass index, alanine aminotransferase (ALT), triglycerides (TG), and total cholesterol (TC) were found to be significantly correlated to higher scores. The following algorithm, derived from a 3,275 member training group, for predicting the extent of fatty liver infiltration was then constructed using these parameters.
In (π₁/π₀) = -8.360-0.065*Gender+0.010*age+0.256*BMI+0.024*ALT+0.03*TG+0.002*TC
In (π₂/π₀)= -19.0.92+0.482*Gender+0.043*age+0.529*BMI+0.046*ALT+0.005*TG+0.005*TC
π₀: the probability of non fatty liver.
π₁: the probability of degree 1 fatty liver.
π₂: the probability of degree 2-3 fatty liver.
π₀ + π₁ + π₂ = 1
The resulting algorithm was tested for its predictive power a 1,065 member validation group. The algorithm predicted the actual ultrasound fatty liver score in the validation group with 87.9, 14.2, and 72.6% accuracy for those with no, grade 1, and grade 2-3 fatty liver, respectively. For prediction of grade 2-3 fatty liver, its sensitivity was 70.8%, its specificity 85.2%, its positive predictive power 63.2% and its negative predictive power 88.8%. Conclusions. The algorithm developed here is fast and has substantial predictive power for grade 2-3 fatty liver. No specialized equipment or expertise is needed, and it can be easily used by the general practitioner to predict the extent of fatty infiltration in cases of NAFLD.

REFERENCES

1. Yan E, Durazo F, Tong M, Hong K. Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutr Rev 2007; 65(8 Pt 1): 376-84.

2. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008; 53: 1358-63.

3. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50(Suppl.): S412-6. Epub 2008 Dec 12.

4. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 2008; 17(3): 255-60.

5. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population in Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40(8): 745-52.

6. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009; 25(3): 230-7.

7. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28(4): 339-50.

8. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189(6): W320-3.

9. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopes R, McCullough AJ. Validity of real time ultrasound in the diagnosis of steatosis: a prospective study. Hepatol 2009; 51: 1061-7.

10. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10 doi:10.1186/1476-5926-4-10.

11. Bedogni G, Belletani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 doi: 10.1186/ 1471-230X-6-33.

12. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive markers for the screening of fibrosis, steatosis, and steatohepatitis in patients with metabolic risk factors: FibroTest-Fibro-MaxTM Experience. J Gastroenterol Liver Dis 2008; 17(2): 187-91.

13. Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K, Omagari K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008; 28(4): 519-24.

14. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13(47): 6419-24.

15. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, Park DI, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006; 55(12): 1604-9.

16. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008; 53(5): 1358-63.

17. Alazmi WM, Regev A, Molina EG, Schiff ER. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006; 51(10): 1725-9.

18. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.

19. Duseja A, Das A, Das R et al. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007; 52(9): 2368-74.

20. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.

21. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. (Editorial). Gastroenterology 2003; 124(1): 248-50.